ArticleStem cell research & therapy2022

Genetic correction of concurrent α- and β-thalassemia patient-derived pluripotent stem cells by the CRISPR-Cas9 technology.

Lingli Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.